Hyperfine, Inc. — Director's Dealing 2021

Dec 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Hyperfine, Inc. (HYPR)
CIK: 0001833769
Period of Report: 2021-12-22

Reporting Person: Siddiqui Khan (CMO and Chief Strategy Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-22	Stock Option (right to buy)	$3.76	A	104800	Acquired	2030-01-27	Class A Common Stock (104800)	Direct
2021-12-22	Stock Option (right to buy)	$3.76	A	130345	Acquired	2030-01-27	Class A Common Stock (130345)	Direct
2021-12-22	Stock Option (right to buy)	$3.27	A	54037	Acquired	2031-04-14	Class A Common Stock (54037)	Direct
2021-12-22	Stock Option (right to buy)	$5.24	A	1796	Acquired	2031-05-12	Class A Common Stock (1796)	Direct

Footnotes

F1: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal

F2: (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in connection with the Mergers in exchange for a stock option to acquire 320,000 shares of Hyperfine common stock for $1.23 per share.

F3: The shares underlying this option vested as to 25% on December 31, 2020, with the remainder of the options vesting in equal monthly installments, over the following three years, subject to Dr. Siddiqui's continued service on each vesting date.

F4: Received in connection with the Mergers in exchange for a stock option to acquire 398,000 shares of Hyperfine common stock for $1.23 per share.

F5: The shares underlying this option vested as to 25% on December 31, 2020, with the remainder of the options vesting in equal monthly installments, over the following three years, subject to Dr. Siddiqui's continued service on each vesting date.

F6: Received in connection with the Mergers in exchange for a stock option to acquire 165,000 shares of Hyperfine common stock for $1.23 per share.

F7: The shares underlying this option vest in forty eight equal monthly installments beginning on January 31, 2021, subject to Dr. Siddiqui's continued service through the applicable vesting date.

F8: Received in connection with the Mergers in exchange for a stock option to acquire 10,000 shares of Liminal common stock for $0.94 per share.

F9: The shares underlying this option vest in forty eight equal monthly installments beginning on October 31, 2020, subject to Dr. Siddiqui's continued service through the applicable vesting date.